Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes

por Tavira, Beatriz, Barcenilla, Hugo, Wahlberg, Jeannette, Achenbach, Peter, Ludvigsson, Johnny, Casas, Rosaura
Publicado 2018

Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)

por Casas, Rosaura, Dietrich, Fabrícia, Puente-Marin, Sara, Barcenilla, Hugo, Tavira, Beatriz, Wahlberg, Jeannette, Achenbach, Peter, Ludvigsson, Johnny
Publicado 2022